Biotech Values

[DewDiligence]

GILD licenses gene-editing approach to HBV from (private) Precision Biosciences:

https://finance.yahoo.com/news/gilead-sciences-precision-biosciences-announce-123100236.html

Under the terms of the collaboration agreement, Precision will be primarily responsible for the development, formulation, and preclinical evaluation of the investigational nucleases, and Gilead will be responsible for the clinical development and commercialization of potential therapies. Gilead will fully fund the research and development. Precision is eligible to receive milestone payments of up to an aggregate of $445 million and tiered royalties that go up to the mid-teens for commercial products developed through the collaboration.

The intention is to edit cccDNA and thereby kill it off. It will probably take several years to know whether this idea will work.